Replies to post #301050 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

will greatly facilitate or prompt FDA approval of blarcamesine for Parkinson's disease dementia.

By prompt, I am assuming you mean after a positive readout from the planned P3 PDD trial perhaps some time in 2023?

[IhidfromtheX]

Don't forget the initial 10 off of Systolic blood pressure. I belive we have the patients now to figure out if that is a happening!